Global Pricing “Hinders European Arthritis Drug Access”

RA Guy Community News

Many of Europe’s nearly 2 million rheumatoid arthritis patients are still unable to access effective new biologic treatments, and whether they can do so or not is largely dependent on where they live, says a new study…

The largest differences in access are due to a global price for the drugs and large differences in wealth among the 30 nations, says the study.

Read More: http://www.pharmatimes.com/WorldNews/article.aspx?id=16729